Al Sandrock (Biogen via YouTube)

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

Even as Bio­gen ex­ecs scram­bled to de­fend Aduhelm and paint a rosy fu­ture the drug promis­es to un­leash, R&D chief Al San­drock re­as­sured an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.